A Virtual Forum Designed to Address Clinical Challenges with the Goal to Improve Patient Outcomes
September 22, 2021 – September 25, 2021
This meeting will provide clinical trial safety and efficacy data for approved and emerging agents and combinations being studied for the treatment of hematologic malignancies. Frontline and relapsed/refractory disease are eligible to be discussed. Within each section, there will be a heavy focus on contextualizing the data and application to clinical practice. The impact of COVID-19 on the care of patients with hematologic malignancies can be included throughout, per faculty discretion.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.
Session I: Stet clita kasd gub consetetur
Session II: At vero eos et accusam
Session III: Sed diam nonumy eirmod tempor
Session V: No sea takimata sanctus est
Session IV: Labore et dolore magna aliquyam erat, sed diam voluptua
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et.
This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!
[bold]For every registrant, Medscape Oncology will make a donation to The Leukemia & Lymphoma Society (LLS)[/bold]. As a bonus, Medscape will contribute an [italic]additional[/italic] $10 for each registrant who participates in the conference.
LLS is at the forefront of research, advocacy and patient support in the blood cancer community.
[bold]The Leukemia & Lymphoma Society is not involved in the development and does not endorse the content for this conference.[/bold]
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.